BiotechTube

Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Seasonal Allergic Rhinitis

Conditions

Seasonal Allergic Rhinitis

Trial Timeline

Dec 1, 2009 → Feb 1, 2010

NCT ID
NCT01010971

About Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + Placebo

Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + Placebo is a phase 3 stage product being developed by Sumitomo Pharma for Seasonal Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01010971. Target conditions include Seasonal Allergic Rhinitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01010971Phase 3Completed

Competing Products

20 competing products in Seasonal Allergic Rhinitis

See all competitors
ProductCompanyStageHype Score
Bilastine + Desloratadine + PlaceboYuhanPhase 3
77
ASP4070 + PlaceboAstellas PharmaPhase 2
52
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
52
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
52
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
77
80 mcg Ciclesonide + 160 mcg Ciclesonide + PlaceboSumitomo PharmaPhase 3
77
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)Glenmark PharmaceuticalsPhase 2
52
Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal sprayGlenmark PharmaceuticalsPhase 2
52
JNJ38224342 + JNJ38224342/placebo + JNJ38224342/placebo + JNJ38224342/placeboJohnson & JohnsonPhase 1
33
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide HFA + Ciclesonide HFA + Ciclesonide HFA + PlaceboAstraZenecaPhase 2
52
budesonide + PlaceboAstraZenecaPhase 2
52
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide Nasal SprayAstraZenecaPhase 3
77
Budesonide + Fluticasone propionate + PlaceboAstraZenecaPhase 3
77
Ciclesonide + Ciclesonide PlaceboAstraZenecaPhase 3
77
loratadineMerckPre-clinical
23
MK0524MerckPhase 2
52
loratadine; montelukastMerckPhase 3
77

Other Products from Sumitomo Pharma

BlonanserinApproved
85
Mosapride + domperidoneApproved
85
levalbuterol HCl + albuterol SulfateApproved
85
LurasidoneApproved
85
placebo, isotonic ciclesonide, hypotonic ciclesonideApproved
85